secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001493152-24-042193
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience awarded $10M from ARPA-H to develop HPV treatment candidate DARE-HPV
--------------------------------------------------------------------------------

- Award of $10M from ARPA-H Sprint for Women's Health; milestone-based payments over 24 months.
- DARE-HPV: investigational fixed-dose lopinavir/ritonavir vaginal insert for HPV-related cervical diseases.
- Milestones include IND-enabling studies, FDA IND clearance, clinical supplies, and Phase 2 trial start.
- More than half of award payable in first 12 months; ARPA-H retains certain IP rights including march-in.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224042193/0001493152-24-042193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224042193/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer